Literature DB >> 19509388

Mendelian randomization: nature's randomized trial in the post-genome era.

George Thanassoulis, Christopher J O'Donnell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19509388      PMCID： PMC3457799          DOI： 10.1001/jama.2009.812

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  16 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.

Authors:  May M Luke; John P Kane; Dongming M Liu; Charles M Rowland; Dov Shiffman; June Cassano; Joseph J Catanese; Clive R Pullinger; Diane U Leong; Andre R Arellano; Carmen H Tong; Irina Movsesyan; Josephina Naya-Vigne; Curtis Noordhof; Nicole T Feric; Mary J Malloy; Eric J Topol; Marlys L Koschinsky; James J Devlin; Stephen G Ellis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-06-14       Impact factor: 8.311

3.  Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.

Authors:  J Danesh; R Collins; R Peto
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

4.  Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study.

Authors:  F Kronenberg; M F Kronenberg; S Kiechl; E Trenkwalder; P Santer; F Oberhollenzer; G Egger; G Utermann; J Willeit
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

5.  Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.

Authors:  E Boerwinkle; C C Leffert; J Lin; C Lackner; G Chiesa; H H Hobbs
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

6.  High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort.

Authors:  Henry D Wu; Lars Berglund; Clarito Dimayuga; Jeffery Jones; Robert R Sciacca; Marco R Di Tullio; Shunichi Homma
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.

Authors:  Dov Shiffman; Ellen S O'Meara; Lance A Bare; Charles M Rowland; Judy Z Louie; Andre R Arellano; Thomas Lumley; Kenneth Rice; Olga Iakoubova; May M Luke; Bradford A Young; Mary J Malloy; John P Kane; Stephen G Ellis; Russell P Tracy; James J Devlin; Bruce M Psaty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-11-01       Impact factor: 8.311

9.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

Authors:  Pia R Kamstrup; Anne Tybjaerg-Hansen; Rolf Steffensen; Børge G Nordestgaard
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  45 in total

1.  Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease.

Authors:  Caroline L Relton; George Davey Smith
Journal:  Int J Epidemiol       Date:  2012-02       Impact factor: 7.196

2.  Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: the Genetic Counseling/lifestyle Change (GC/LC) Study for Diabetes Prevention.

Authors:  Richard W Grant; James B Meigs; Jose C Florez; Elyse R Park; Robert C Green; Jessica L Waxler; Linda M Delahanty; Kelsey E O'Brien
Journal:  Clin Trials       Date:  2011-10       Impact factor: 2.486

Review 3.  Genetics of Dyslipidemia and Ischemic Heart Disease.

Authors:  Kavita Sharma; Ragavendra R Baliga
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

Review 4.  Insight into rheumatological cause and effect through the use of Mendelian randomization.

Authors:  Philip C Robinson; Hyon K Choi; Ron Do; Tony R Merriman
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

5.  State- and trait-dependent associations of vitamin-D with brain function during aging.

Authors:  Alexandra M Kueider; Toshiko Tanaka; Yang An; Melissa H Kitner-Triolo; Elango Palchamy; Luigi Ferrucci; Madhav Thambisetty
Journal:  Neurobiol Aging       Date:  2015-11-18       Impact factor: 4.673

6.  Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis.

Authors:  Xinghao Yu; Ting Wang; Shuiping Huang; Ping Zeng
Journal:  J Hum Genet       Date:  2020-10-25       Impact factor: 3.172

7.  Blood HER2 and Uromodulin as Causal Mediators of CKD.

Authors:  Jennifer Sjaarda; Hertzel C Gerstein; Salim Yusuf; Darin Treleaven; Michael Walsh; Johannes F E Mann; Sibylle Hess; Guillaume Paré
Journal:  J Am Soc Nephrol       Date:  2018-03-06       Impact factor: 10.121

Review 8.  Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.

Authors:  Amit V Khera; Daniel J Rader
Journal:  Trends Cardiovasc Med       Date:  2009-08       Impact factor: 6.677

9.  Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile.

Authors:  Lisanne L Blauw; Raymond Noordam; Sebastian Soidinsalo; C Alexander Blauw; Ruifang Li-Gao; Renée de Mutsert; Jimmy F P Berbée; Yanan Wang; Diana van Heemst; Frits R Rosendaal; J Wouter Jukema; Dennis O Mook-Kanamori; Peter Würtz; Ko Willems van Dijk; Patrick C N Rensen
Journal:  Eur J Hum Genet       Date:  2018-11-12       Impact factor: 4.246

Review 10.  Large-Scale Genomic Biobanks and Cardiovascular Disease.

Authors:  Aeron M Small; Christopher J O'Donnell; Scott M Damrauer
Journal:  Curr Cardiol Rep       Date:  2018-03-08       Impact factor: 2.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.